Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | LTA4H | P09960 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679055 | 0.91 | KDM4E (0.65) | KDM4EPOLBHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL22831358 | 0.89 | KCNH2 (0.53) | KDM4EPOLBHRH3SMN1; SMN2 | |
| SCHEMBL23074661 | 0.85 | KDM4E (0.50) | KDM4EPOLBHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL14349614 | 0.85 | KEAP1 (0.59) | KDM4EPOLBHRH3LTA4HKEAP1 | |
| SCHEMBL17300723 | 0.84 | KDM4E (0.60) | KDM4EPOLBHRH3LTA4HKEAP1 | |
| SCHEMBL17300726 | 0.84 | CHRNB2 (0.51) | KDM4EPOLBHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL17300733 | 0.82 | KDM4E (0.46) | KDM4EPOLBHRH3LTA4HALDH1A1 | |
| SCHEMBL11947325 | 0.82 | KDM4E (0.47) | KDM4EPOLBHRH3LTA4HKEAP1 | |
| SCHEMBL11262665 | 0.81 | EBP (0.58) | KDM4EHRH3LTA4H | |
| SCHEMBL22248702 | 0.81 | HRH3 (0.62) | KDM4EPOLBHRH3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582963-B2 | Separation matrix and method of separation | CYTIVA BIOPROCESS R&D AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12343702-B2 | Anionic exchange-hydrophobic mixed mode chromatography resin | BIO-RAD LABORATORIES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250196100-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | BIO-RAD LABORATORIES, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4142930-B1 | SEPARATION MATRIX AND METHOD OF SEPARATION | PURIDIFY LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7176231-B2 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | KDM4E 3659/4885POLB 4243/4885HRH3 358/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | KDM4E 3638/4885POLB 4119/4885HRH3 380/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KDM4E 4157/4885POLB 3123/4885HRH3 3296/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KDM4E 4157/4885POLB 3123/4885HRH3 3296/4885 |
| US-20250196100-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | SLC7A1, ABCG2, MSR1 | KDM4E 3608/4885POLB 4335/4885HRH3 6/4885 |
| US-12582963-B2 | Separation matrix and method of separation | EPCAM, PA2G4, MAG | KDM4E 1482/4885POLB 4374/4885HRH3 1754/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | KDM4E 2909/4885POLB 1221/4885HRH3 2959/4885 |
| US-12343702-B2 | Anionic exchange-hydrophobic mixed mode chromatography resin | FCGRT, PBRM1, BCR | KDM4E 1451/4885POLB 4123/4885HRH3 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.